Novel interactomics approach identifies ABCA1 as direct target of evodiamine, which increases macrophage cholesterol efflux.
Limei WangPierre EftekhariDaniel SchachnerIrena D IgnatovaVeronika PalmeNicole SchilcherAngela LadurnerElke H HeissHerbert StanglVerena M DirschAtanas G AtanasovPublished in: Scientific reports (2018)
Evodiamine, a bioactive alkaloid from the fruits of the traditional Chinese medicine Evodia rutaecarpa (Juss.) Benth. (Fructus Evodiae, Wuzhuyu), recently gained attention as a dietary supplement for weight loss and optimization of lipid metabolism. In light of its use by patients and consumers, there is an urgent need to elucidate the molecular targets affected by this natural product. Using a novel interactomics approach, the Nematic Protein Organisation Technique (NPOT), we report the identification of ATP-binding cassette transporter A1 (ABCA1), a key membrane transporter contributing to cholesterol efflux (ChE), as a direct binding target of evodiamine. The binding of evodiamine to ABCA1 is confirmed by surface plasmon resonance (SPR) experiments. Examining the functional consequences of ABCA1 binding reveals that evodiamine treatment results in increased ABCA1 stability, elevated cellular ABCA1 protein levels, and ultimately increased ChE from THP-1-derived human macrophages. The protein levels of other relevant cholesterol transporters, ABCG1 and SR-B1, remain unaffected in the presence of evodiamine, and the ABCA1 mRNA level is also not altered.
Keyphrases
- binding protein
- weight loss
- end stage renal disease
- endothelial cells
- low density lipoprotein
- chronic kidney disease
- newly diagnosed
- dna binding
- protein protein
- ejection fraction
- adipose tissue
- amino acid
- type diabetes
- genome wide
- transcription factor
- gene expression
- roux en y gastric bypass
- prognostic factors
- working memory
- single molecule
- peritoneal dialysis
- small molecule
- pluripotent stem cells
- glycemic control